Dinaciclib, a drug that targets CDK1, CDK2, CDK5, and CDK9, has demonstrated efficacy in the treatment of breast cancer by reducing the expression of stem cell markers and decreasing cancer cell viability [68]. This evidence concerns the gene CDK1 and breast cancer.